FDA Approves Lilly's Omvoh® (Mirikizumab-Mrkz) For Crohn's Disease, Expanding Its Use To The Second Major Type Of Inflammatory Bowel Disease
In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic respons ...
STAT13h
Eli Lilly is considering offering more Zepbound doses in vials at lower cost
Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...